Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions International, Inc. (TSOI) generates a steady flow of news centered on immune modulation, stem cell therapy, immunotherapy, and nutraceutical development. This news page aggregates company announcements so readers can follow how its clinical-stage programs, patents, and subsidiaries evolve over time.
Recent press releases highlight progress with the company’s JadiCell universal donor stem cell product in areas such as lung inflammation, COVID-19–related conditions, ARDS, epilepsy, and ALS. News items also cover mechanistic discoveries about how JadiCells interact with immune cells, as well as data suggesting that these cells may enhance gene therapy–mediated production of therapeutic cells.
Another major stream of updates involves the nutraceutical QuadraMune. The company has announced multiple patents related to QuadraMune’s effects on immune pathways, including natural killer cell activity, viral inhibition, brain protection, and modulation of regulatory T cells. These developments are reflected in patent-related news and scientific commentary from company representatives.
Therapeutic Solutions International also issues news about its subsidiaries and pre–spin-off entities, such as Campbell Neurosciences in suicide prevention, Res Nova Bio in oncology immunotherapy, Epilepsy Bio in epilepsy, and ALS Biologics in ALS. Announcements may describe clinical observations under Right To Try, plans for public listings, loyalty dividends of subsidiary shares, and strategic positioning of intellectual property.
In addition, the company has released statements on legal actions and corporate decisions, including its plan to voluntarily delist and "go dark" from the public markets. Investors and observers can use this news feed to review historical announcements on clinical progress, patents, subsidiary formation, legal matters, and capital markets strategy related to TSOI.
Therapeutic Solutions International, Inc. (OTC Markets: TSOI) announced the filing of a patent for a unique cell designed to train the immune system to target cancerous blood vessels while preserving healthy vessels. This innovation builds on prior findings showing StemVacs' ability to suppress new blood vessel formation. The company's new product, StemVacs-V™, is a chimeric cell derived from engineered iPSC cells, demonstrating selective killing of malignant blood vessels, which could offer significant therapeutic potential.
Therapeutic Solutions International, Inc. (OTC Markets: TSOI) reported new data on its StemVacs-V product, which shows potential anticancer benefits by activating dual immunological mechanisms. In animal studies with B16 melanoma, treatment led to enhanced T cell responses and increased infiltration of macrophages and natural killer cells. The Company aims to advance StemVacs-V towards FDA filing, highlighting its capacity for large-scale production, customization for various cancers, and safety in preliminary studies.
Therapeutic Solutions International (OTC Markets: TSOI) filed a patent for a revolutionary gene-modified stem cell-derived universal donor dendritic cell cancer immunotherapy, named StemVacs-V™. This therapy activates the immune system to target cancer while being resistant to immune suppression. Dr. James Veltmeyer emphasized the uniqueness of this approach, leveraging the consistency of pluripotent stem cells. Previous treatments have shown promise in enhancing natural killer cell activity. The patent data indicates an effective anti-tumor response in preclinical studies.
Therapeutic Solutions International (OTC: TSOI) announced promising preclinical results alongside a patent filing for using manipulated cord blood-derived monocytes to prevent suicidal ideations and brain inflammation. Research demonstrated that these monocytes protect neurological functions and suppress immunological proteins linked to suicidal thoughts. The company’s approach, enhanced by oxytocin pretreatment, has shown potential for developing new cell therapies, emphasizing collaboration with Campbell Neurosciences to translate findings into clinical applications.
Therapeutic Solutions International, Inc. (OTC Markets: TSOI) has secured approval to market its dietary supplements on the RangeMe B2B platform, significantly enhancing its sales potential. This platform connects the company with over 10,000 retail buyers, allowing direct engagement regarding products like NanoStilbene, ProJuvenol, QuadraMune, and NanoPSA. The Director of Sales, Serena Robella, expressed optimism about the new market opportunities. This follows a recent announcement of the company joining Amazon, indicating a strong push into both online and brick-and-mortar sales.
Therapeutic Solutions International (OTC Markets: TSOI) has received approval to sell its dietary supplements on Amazon, marking a significant entry into the e-commerce market. The initial offerings include NanoStilbene™, ProJuvenol™, and QuadraMune™, which are expected to tap into Amazon's vast customer base of hundreds of millions. Serena Robella, Director of Sales, expressed enthusiasm for expanding product accessibility, while CEO Timothy Dixon highlighted the potential for rapid sales growth through Amazon's platform.
On February 25, 2021, Therapeutic Solutions International, Inc. (TSOI) reported positive preliminary results from its clinical trial, 'Validation of Kaihani Score for Gambling Addiction'. The study showed a significant correlation between neuromodulatory protein levels and gambling addiction severity, with patients showing varying levels of the protein based on their addiction status. TSOI emphasizes the potential of the immune system in understanding and treating mental health issues. The ongoing trial aims to recruit additional participants for further validation of the Kaihani Score™.
Therapeutic Solutions International (TSOI) announced a patent application for its StemVacs™ technology, which utilizes cancer-specific antigen BORIS to generate T cells that target and destroy cancer stem cells. Research highlights BORIS's role in cancer cell survival, with implications for treating aggressive cancers like breast cancer, glioma, and leukemia. The company's approach aims to overcome limitations of current cancer therapies, potentially positioning StemVacs™ as a revolutionary treatment by focusing on eliminating the root cause of cancer.
Therapeutic Solutions International, Inc. (TSOI) announced that its spin-off, Campbell Neurosciences, completed a successful 30-patient clinical trial examining blood levels of an inflammatory cytokine related to suicidal ideation. Results showed significant differences in cytokine levels across three patient groups, with Group 3 having the highest levels at 45.8 ±7.7 pg/ml. This trial is a step towards developing a blood-based test for suicidal ideation, addressing a critical public health issue for young people. The company is exploring implementation strategies for the Campbell Score within the mental health sector.
Therapeutic Solutions International (OTC Markets: TSOI) appointed Dr. Boris Minev to its Scientific Advisory Board, enhancing its expertise in cancer immunotherapy. Dr. Minev, a recognized tumor immunologist, has a history of success in the field, notably developing Melacine®, the first tumor vaccine to gain regulatory approval. His experience also includes leadership roles in immunotherapy projects. The company recently acquired rights to JadiCellsä, which have shown safety and efficacy in clinical trials for lung injuries, indicating potential for future applications in treating serious conditions.